79 completed, 23 terminated, 4 withdrawn, 3 active not recruiting. 111 Phase 1, 43 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 111 | Completed 79, Terminated 23, Withdrawn 4, Active not recruiting 3, Recruiting 1, Unknown 1 |
| Phase 2 | 43 | Completed 31, Terminated 10, Unknown 1, Withdrawn 1 |
Follow RAD001: new trials by email Literature Review of RAD001 trials Research Report on RAD001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies DFF332, RAD001, PDR001 - Carcinoma, Renal Cell | Phase 1 | Terminated | Novartis Pharmaceuticals | 40 | 2021-11-30 | 2026-03-03 |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) Everolimus, Trametinib - Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma | Phase 1 | Recruiting | University of California, San Francisco | 50 | 2020-12-09 | 2026-08-18 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 22 | 2018-01-13 | 2021-08-27 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
| RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome RAD001, Placebo - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 46 | 2017-06-12 | 2025-02-17 |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat PDR001, LCL161, Everolimus - Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 298 | 2016-10-14 | 2023-01-11 |
| Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer Ceritinib, Everolimus, Laboratory Biomarker Analysis - ALK Positive, Locally Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 37 | 2016-06-22 | 2026-11-12 |
| Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Brentuximab Vedotin, Everolimus, Laboratory Biomarker Analysis - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1 | Terminated | Mayo Clinic | 10 | 2016-02-04 | 2019-12-12 |
| Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer everolimus, eribulin mesylate, pharmacological study - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | City of Hope Medical Center | 27 | 2014-11-17 | 2026-10-28 |
| LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma Everolimus, LDE 225 - Esophageal Cancer | Phase 1 | Completed | M.D. Anderson Cancer Center | 25 | 2014-11-10 | 2020-06-11 |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer everolimus, bendamustine hydrochloride - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | University of California, Davis | 20 | 2014-10-01 | 2019-01-04 |
| Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer Everolimus, Enzalutamide - Prostate Cancer | Phase 1 | Completed | SCRI Development Innovations, LLC | 38 | 2014-10-01 | 2021-05-04 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Everolimus, Laboratory Biomarker Analysis, Letrozole - Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive | Phase 1 | Completed | M.D. Anderson Cancer Center | 37 | 2014-07-17 | 2020-12-19 |
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease TheraSphere, Everolimus, Phone Call - Liver Cancer | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2014-05-01 | 2014-07-22 | |
| Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma AEB071, Everolimus - CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Novartis Pharmaceuticals | 31 | 2013-12-05 | 2020-12-19 |
| Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer ribociclib (LEE011), Exemestane, Everolimus (RAD001) - Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 132 | 2013-09-06 | 2021-04-13 |
| RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. RAD001, Imatinib - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2013-09-01 | 2015-05-15 | |
| Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer RAD001, Gemcitabine, Cisplatin - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Center, Korea | 23 | 2013-08-01 | 2017-10-03 |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis lapatinib ditosylate, everolimus, capecitabine - Central Nervous System Metastases, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 9 | 2013-06-26 | 2019-11-12 |
Showing 20 of 111. Sign in to see all of them.
Breast Neoplasms (14) · Neoplasm Metastasis (12) · Neuroendocrine Tumors (8) · Carcinoma, Non-Small-Cell Lung (7) · Hodgkin Disease (7) · Lung Neoplasms (7) · Carcinoma, Renal Cell (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Mantle-Cell (6) · Neoplasms (6) · Recurrence (6) · Colorectal Neoplasms (5) · Lymphoma, Follicular (5) · Multiple Myeloma (5)
Novartis Pharmaceuticals (16) · M.D. Anderson Cancer Center (15) · Dana-Farber Cancer Institute (8) · Emory University (7) · Mayo Clinic (7) · Children's Hospital Medical Center, Cincinnati (4) · Fox Chase Cancer Center (3) · Vanderbilt-Ingram Cancer Center (3) · City of Hope Medical Center (2) · Massachusetts General Hospital (2) · National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (2) · SCRI Development Innovations, LLC (2) · University of California, Davis (2) · University of Utah (2)
United States (96) · France (8) · Germany (6) · Spain (5) · Belgium (4) · Italy (4) · Netherlands (4) · South Korea (4) · Australia (3) · Hong Kong (3) · Taiwan (3) · China (2) · Denmark (2) · Japan (2) · Brazil (1)
Filip Janku (2) · Ingrid Mayer, MD (2) · Nabil F. Saba, MD (2) · Sunil Sharma, MD (2) · Suresh Ramalingam, MD (2) · Amanda Townsend, MBBS (1) · Andrew X. Zhu, MD, PhD (1) · Barbara Burtness (1) · Bassel El-Rayes, MD (1) · Benjamin Tan, M.D. (1) · Brian Costello (1) · Brian Hill, MD, PhD (1) · Brian Wolpin, MD (1)
PMID 21730275, PMID 19192962, PMID 21047224, PMID 22262746, PMID 22736724, PMID 23325902, PMID 23475104, PMID 23580238, PMID 23798472, PMID 24761838, PMID 24912489, PMID 25103371, PMID 25450031, PMID 25900182, PMID 25982012, PMID 26139427, PMID 26381530, PMID 28357727, PMID 29023494, PMID 29451701, PMID 30220708, PMID 30302599, PMID 30424962, PMID 30542377, PMID 31654285, PMID 31703728, PMID 31967673, PMID 32704173, PMID 33055173, PMID 33115815, PMID 33738668, PMID 35594551, PMID 37314501, PMID 39863139
P30CA015083 (3), 2008 (2), P30CA016672 (2), 2004 (1), P30CA008748 (1), P30CA043703 (1), P30CA068485 (1), P30CA072720 (1), R01FD003743 (1), U01CA062461 (1), U01CA069856 (1), U54NS092090 (1), UM1CA081457 (1)